Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
ReWalk Robotics (Nasdaq: RWLK) is an innovative medical device company. We design,...
ReWalk Robotics (Nasdaq: RWLK) is an innovative...
Omnicell, Inc., is a leading provider of solutions targeting patient safety and op...
Omnicell, Inc., is a leading provider of soluti...
Akorn, Inc. is a niche pharmaceutical company that develops, manufactures and mark...
Akorn, Inc. is a niche pharmaceutical company t...
Conatus Pharmaceuticals is a biotechnology company focused on the development and ...
Conatus Pharmaceuticals is a biotechnology comp...
Verona Pharma plc is a clinical stage biopharmaceutical company focused on the dev...
Verona Pharma plc is a clinical stage biopharma...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
BeiGene, Ltd. (âBeiGeneâ) is a commercial-stage biotechnology company focused ...
BeiGene, Ltd. (âBeiGeneâ) is a commercial-s...
Join the National Investor Network and get the latest information with your interests in mind.